LGI1-antibody Patients Follow-up

• Conditions: Anti-LGI1 Encephalitis

• Registration Number: NCT04106765
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Autoimmune encephalitis involve autoantibodies targeting central nervous system, and particularly the synapse or its structure like for LGI1 protein. Anti-LGI1 encephalitis is revealed by an inflammation of the limbic system, with mainly temporal lobe, faciobrachial dystonic or generalized seizures, and cognitive disorders.

This disease is rare and its clinical, EEG and radiological characterisation is not sufficiently established. The investigators will evaluate these three aspects for the anti-LGI1 cohort of patients of the National Reference Center of autoimmune encephalitis.

Detailed Description

Not available

Study Timeline

• Status Verified: 2019-09
• Study First Submitted: 2019-09-25
• Study First Submitted QC: 2019-09-26
• Study First Posted: 2019-09-27
• Last Update Submitted: 2019-10-11
• Last Update Posted: 2019-10-15
• Study Start: 2019-10-30
• Primary Completion: 2020-09-30
• Study Completion: 2020-12-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 192

Inclusion Criteria

• Age > 18 years
• Diagnosis of anti-LGI1 encephalitis based on sera or CSF samples in the National Reference Center of autoimmune encephalitis from 2011/06 to 2019 july 1st.
• Clinical follow-up in France

Read More

Exclusion Criteria

• Anti-LGI1 antibody associated with another encephalitis antibody
• Foreign follow-up

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evolution of epileptic seizures	12 MONTHS

Trial Locations

Locations (1)

Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes; 🇫🇷 Lyon, France